# the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

> **NCT04978753** · PHASE2 · UNKNOWN · sponsor: **Li-kun Chen** · enrollment: 54 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04978753
- **Lead sponsor:** Li-kun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2022-05-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2021-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04978753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04978753, "the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04978753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*